Despite the challenges of pandemic disruptions, drug
developers advance promising therapies for conditions, including
Alzheimer's, diabetes and asthma
Report also examines key therapeutic development areas to
watch including mRNA, CRISPR, AI-driven drug discovery and
more
LONDON, Jan. 10, 2022 /PRNewswire/ -- Clarivate
Plc (NYSE: CLVT), a global leader in providing trusted
information and insights to accelerate the pace of innovation,
today announced the release of its annual Drugs to Watch™ report,
identifying drugs entering the market or launching key indications
in 2022 which are predicted to achieve blockbuster status by 2026.
Leveraging Clarivate data and insights, analysts identified
seven late-stage experimental treatments that they forecast will
deliver annual sales of more than $1
billion within five years. These treatments span a
remarkably diverse set of therapeutic areas, from conditions like
Alzheimer's disease (AD), asthma and type 2 diabetes mellitus
(T2DM), which afflict tens of millions of patients worldwide, to
rare diseases, such as transthyretin amyloidosis (ATTR), among
others.
The report also offers an in-depth analysis of key COVID-19
vaccines and therapies along with key therapeutic development areas
to watch, such as cell and gene therapies, CRISPR, drug discovery
driven by artificial intelligence and machine learning, RNA and
targeted cancer therapies. In addition, the report examines
blockbuster drugs and biologics facing generic competition due to
U.S. patent expirys in 2022.
Navigating the global healthcare landscape is increasingly
complex, and discovering, developing and commercializing successful
treatments that change patient lives can be challenging, especially
during today's unprecedented times. The Drugs to Watch report
highlights experimental treatments with great promise to realize
improved patient outcomes and efforts to finance the next
generation of innovative medicines. Through adaptation,
improvisation and crowdsourcing solutions, the companies behind
these promising treatments are advancing a broad array of
innovative treatment candidates – leveraging deep expertise in
their relevant therapeutic areas and long-term strategies for
pursuing therapeutic solutions for these conditions.
Among new drugs and biologics that have either won approval or
are poised to do, Clarivate has identified seven treatments that it
believes are likely to achieve blockbuster status in the next five
years. The 2022 Drugs to Watch, include:
- Adagrasib, developed by Mirati Therapeutics Inc and Zai Lab
Limited - This long-awaited, targeted treatment will likely be
the first such treatment option in patients with colorectal cancer
(CRC) with the KRASG12C mutation, who historically have had very
few treatment options. The common variants of the KRAS oncoprotein
are traditionally considered intractable drug targets which makes
the forecasted entry of a KRAS inhibitor for patients with
mutation-positive solid tumors so monumental.
- Faricimab, developed by Roche and Chugai Pharmaceutical
- For patients with diabetic macular edema (DME) or wet age-related
macular degeneration (AMD), faricimab offers a potentially more
convenient option as it will be administered less frequently, on
average, than the standard of care. As the first bispecific
antibody to launch in ophthalmology, it also has the potential to
be more efficacious than current standard of care, although data so
far indicates it is non-inferior to the standard of care. Faricimab
is the first dual VEGF/Ang-2 inhibitor to treat DME and wet AMD
(and the first bispecific MAb in the ophthalmology therapeutic area
overall).
- Lecanemab, developed by Eisai Co Ltd and Biogen Inc, and
donanemab, from Eli Lilly and Company - In this underserved
market, anti-Aβ MAbs lecanemab and donanemab are poised to follow
on the heels of the U.S. FDA's landmark accelerated approval of
ADUHELM for the treatment of AD. Lecanemab and donanemab could
offer differentiated clinical profiles, which may be bolstered by
phase 3 results that are expected to be reported beginning in late
2022. Data across clinical trials suggest that sufficient exposure
to optimal doses of anti-Aβ MAb therapy could be clinically
effective in early AD.
- Tezepelumab, developed by Amgen and AstraZeneca -
Tezepelumab is a potential game changer for patients with non-TH2
or TH2-low asthma whose asthma is not well-controlled with inhaled
corticosteroids, the current standard of care. If approved, it
would be a first-in-class biologic for this patient population.
Tezepelumab will likely be a first-line biologic for severe TH2-low
asthma and a treatment option for patients with TH2-high asthma for
whom existing therapies have been less successful.
- Tirzepatide, developed by Eli Lilly and Company -
Tirzepatide offers indication-leading reductions in weight loss and
improvements in glycemic control in a growing patient population,
which has the potential to reduce the incidence of type 2 diabetes
mellitus (T2DM)-related complications. A new treatment that can
more effectively address both weight loss and glycemic control than
existing treatments would potentially be of great benefit to
patient outcomes.
- Vutrisiran, developed by Alnylam Pharmaceuticals - For a
progressive disease with a lot of unmet need, this drug brings
efficacy, a generally favorable safety profile, and improvements in
delivery that will benefit patient quality of life. This patient
population has few treatment options, especially for those with
wild-type ATTR. Not only does this drug enter a relatively
underserved market overall, it also has more convenient dosing than
other ATTR-specific drugs on the market.
Mike Ward, Global Head of Life Sciences
and Healthcare Thought Leadership, Clarivate:
"While pharmaceutical and biotech companies have invested
substantial intellectual capital in the past two years tackling the
challenges wrought by COVID-19, they have also continued to harness
new technologies to create medicines that will provide options for
patients with poorly or currently untreatable diseases that still
represent a significant medical burden. This year's drugs-to-watch
picks, as well as the technologies-to-watch selections, highlight
the robust innovation that is at the heart of the pharma and
biotech sector and will underpin better outcomes for patients in
the future."
Despite the COVID pandemic having disrupted the drug industry in
many ways, from supply chain collapse-induced shortages of key
components1 to clinical trial delays2, pharma
and biotech companies continue to drive major advances in medicine.
Drugmakers are making great strides towards unlocking technologies
that will facilitate personalized medicines. Regulators are showing
an openness to new technologies and methodologies and an eagerness
to address diseases for which there are few or no treatments.
However, it remains critical for companies to prove their value to
win market approval and make them accessible to patients.
Clarivate is committed to comprehensively supporting customers
across the entire drug, device and medical technology lifecycles to
advance human health. By combining patient journey data,
therapeutic area expertise, artificial intelligence and analytics
in ways that unlock hidden insights, data-driven decisions and
accelerating innovation, Clarivate's end-to-end research
intelligence is designed to enable customers to make informed
evidence-based decisions.
The full Drugs to Watch Report is freely available online
here.
For more Drugs to Watch updates and analyses throughout the
year, visit the Drugs to Watch web page and follow
Clarivate for Life Sciences & Healthcare Twitter and
LinkedIn. #DrugstoWatch2022
Methodology for the Clarivate Drugs to Watch 2022
Report
To identify this year's Drugs to Watch, we drew from the
expertise of over 160 analysts covering hundreds of diseases,
drugs and markets and eleven integrated data sets that span the
R&D and commercialization lifecycle, including:
Cortellis Competitive Intelligence™, Disease Landscape &
Forecast, BioWorld™, Drug Timeline & Success Rates, Cortellis
Clinical Trials Intelligence™, Cortellis Generics Intelligence™,
Cortellis Deals Intelligence™, Access & Reimbursement payer
studies, Clarivate Real World Data and Analytics, Web of
ScienceTM, Derwent Innovation™ and other industry
sources including biopharma company press releases, filings and
peer-reviewed publications. Candidate drugs in phase 2 or phase 3
trials, at pre-registration or registration stage, or already
launched early in 2021 were selected for analysis, including drugs
launched for a new indication that could be particularly impactful
on the industry; drugs launched prior to 2021 were excluded. The
dataset was filtered for drugs that had total forecast sales of
$1 billion or more by 2026. Clarivate
experts and analysts evaluated each drug in its individual context,
based on factors such as expected approval or launch dates,
competitive landscape, regulatory status, trial results, market
dynamics and other key factors. Please note that Clarivate
analysts generated the data shown in this report prior to
December 24, 2021.The Drugs to Watch
2021 Report and the treatments referenced in this release are based
on Clarivate's current expectations based on existing data, but
actual results derived from the drugs identified in the Report and
herein may differ significantly.
To learn more about how the evolving R&D landscape
creates many new opportunities and challenges to the traditional
blockbuster model, join Michael Ward
and Kenneth Beers of Clarivate on
January 20, 2022 for a presentation
on "R&D in an Age of Multiplying Modalities and Targets,"
during 2022 Fierce JPM Week. Visit https://www.fiercejpmweek.com/
for more information.
To learn more about Clarivate data products, visit
www.clarivate.com.
About Clarivate
Clarivate™ is a global leader in providing solutions to accelerate
the lifecycle of innovation. Our bold mission is to help customers
solve some of the world's most complex problems by providing
actionable information and insights that reduce the time from new
ideas to life-changing inventions in the areas of science and
intellectual property. We help customers discover, protect and
commercialize their inventions using our trusted subscription and
technology-based solutions coupled with deep domain expertise. For
more information, please visit clarivate.com.
Media Contact
Catherine Daniel
Director, External Communications, Life Sciences &
Healthcare
media.enquiries@clarivate.com
1 Source: Regulatory response to the COVID-19
pandemic: Careful planning to minimize disruptions. Clarivate.
2021.
https://clarivate.com/blog/regulatory-response-to-the-covid-19-pandemic-careful-planning-to-minimize-disruptions/
2 Source: Delays in clinical trials present
opportunities for pharma companies to evolve. Clarivate. 2021.
https://clarivate.com/blog/delays-in-clinical-trials-present-opportunities-for-pharma/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/clarivate-identifies-seven-potential-blockbuster-drugs-in-annual-drugs-to-watch-report-301456684.html
SOURCE Clarivate Plc